Somewhat Positive Press Coverage Somewhat Unlikely to Affect CombiMatrix Corporation (CBMX) Stock Price

News articles about CombiMatrix Corporation (NASDAQ:CBMX) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CombiMatrix Corporation earned a news impact score of 0.18 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 45.5550383483886 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

CombiMatrix Corporation (NASDAQ CBMX) traded up 1.08% during midday trading on Friday, reaching $7.05. 46,349 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $5.84 and a 200 day moving average price of $5.07. The company’s market cap is $20.52 million. CombiMatrix Corporation has a 12 month low of $2.15 and a 12 month high of $7.90.

CombiMatrix Corporation (NASDAQ:CBMX) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.11. CombiMatrix Corporation had a negative return on equity of 35.27% and a negative net margin of 15.53%. The firm had revenue of $4.24 million during the quarter, compared to analysts’ expectations of $3.89 million. On average, equities analysts anticipate that CombiMatrix Corporation will post ($0.52) EPS for the current year.

Several brokerages recently weighed in on CBMX. Ladenburg Thalmann Financial Services lowered shares of CombiMatrix Corporation from a “buy” rating to a “neutral” rating in a research report on Friday, August 4th. Aegis initiated coverage on shares of CombiMatrix Corporation in a research report on Thursday, July 13th. They issued a “buy” rating and a $8.10 price target on the stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect CombiMatrix Corporation (CBMX) Stock Price” was reported by BNB Daily and is owned by of BNB Daily. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/13/combimatrix-corporation-cbmx-given-media-impact-rating-of-0-18-updated.html.

About CombiMatrix Corporation

CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies.

Insider Buying and Selling by Quarter for CombiMatrix Corporation (NASDAQ:CBMX)

Receive News & Ratings for CombiMatrix Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply